Brexit Bites EMA: Huge Staff Losses Freeze Many Projects

The EMA is halting its cherished transparency initiative on study data as it reckons with the fact that many of its employees will not be relocating to its new headquarters in Amsterdam. International collaboration, guidelines development and revision, and the agency's involvement in stakeholder meetings will all be cut back.

PS1808_Biz-Walking_ 668333347_1200.jpg
Staff Are Already Leaving The EMA • Source: Shutterstock

The European Medicines Agency is ditching its policy on the proactive publication of clinical trial data as part of its decision to temporarily suspend or scale-back non-urgent activities to cope with higher-than-expected staff losses due to Brexit. As part of its efforts to protect its core activities relating to drug evaluation and supervision, the agency is also planning to limit its involvement in areas including international collaboration, guidelines development and revision, and attendance at stakeholder meetings.

The EMA had initially estimated that it would lose up to 19% of its staff as a result of it...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography